Cantor Fitzgerald Investment Advisors L.P. Raises Holdings in Pfizer Inc. $PFE

Key Points

• Cantor Fitzgerald Investment Advisors L.P. increased its holdings in Pfizer Inc. by 1.9% during the second quarter, now owning 522,094 shares, valued at approximately $12.7 million.
• Several hedge funds notably raised their positions in Pfizer, with First Pacific Financial boosting its stake by 277.7%.
• Pfizer's recent earnings report showed a profit of $0.78 per share, exceeding estimates, and a revenue increase of 10.3% year-over-year, totaling $14.65 billion for the quarter.

Cantor Fitzgerald Investment Advisors L.P. raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 1.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 522,094 shares of the biopharmaceutical company's stock after purchasing an additional 9,592 shares during the quarter. Cantor Fitzgerald Investment Advisors L.P.'s holdings in Pfizer were worth $12,656,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Woodward Diversified Capital LLC increased its position in shares of Pfizer by 75.4% during the 2nd quarter. Woodward Diversified Capital LLC now owns 29,055 shares of the biopharmaceutical company's stock worth $704,000 after purchasing an additional 12,491 shares during the last quarter. B.O.S.S. Retirement Advisors LLC increased its position in shares of Pfizer by 5.0% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 11,450 shares of the biopharmaceutical company's stock valued at $278,000 after acquiring an additional 543 shares during the last quarter. First Pacific Financial raised its stake in shares of Pfizer by 277.7% in the 2nd quarter. First Pacific Financial now owns 117,471 shares of the biopharmaceutical company's stock valued at $2,848,000 after acquiring an additional 86,372 shares during the period. Eagle Capital Management LLC lifted its holdings in shares of Pfizer by 1.0% in the 2nd quarter. Eagle Capital Management LLC now owns 126,401 shares of the biopharmaceutical company's stock worth $3,064,000 after acquiring an additional 1,257 shares during the last quarter. Finally, Lynx Investment Advisory boosted its position in shares of Pfizer by 5.1% during the 2nd quarter. Lynx Investment Advisory now owns 50,215 shares of the biopharmaceutical company's stock worth $1,217,000 after purchasing an additional 2,433 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on PFE shares. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. UBS Group reiterated a "neutral" rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday. Wall Street Zen downgraded Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday. Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $28.29.

Pfizer Price Performance

PFE stock opened at $27.21 on Thursday. The business's 50-day moving average is $24.59 and its two-hundred day moving average is $24.14. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market capitalization of $154.68 billion, a P/E ratio of 14.47, a P/E/G ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.